Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Joana B, Janelidze, Shorena, Smith, Ruben, Mattsson-Carlgren, Niklas, Palmqvist, Sebastian, Teunissen, Charlotte E, Zetterberg, Henrik, Stomrud, Erik, Ashton, Nicholas J, Blennow, Kaj, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677538/
https://www.ncbi.nlm.nih.gov/pubmed/34259835
http://dx.doi.org/10.1093/brain/awab223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677538/
https://www.ncbi.nlm.nih.gov/pubmed/34259835
http://dx.doi.org/10.1093/brain/awab223

Ejemplares similares